GlassScriptPhysician profile
John J Hart
NPI 1689636698
$3,993.01
in general payments reported to CMS, 2019-2025
38 companies · $784 in 2025
The $784 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $553 · 2020: $321 · 2021: $603 · 2022: $607 · 2023: $728 · 2024: $396 · 2025: $784.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,894 · Education: $14.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,894.45 |
| Education | $14.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $566.04 | 2021-2025 | |
| Lilly USA, LLC | $532.07 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Amgen INC. | $382.57 | 2019-2025 | Evenity, Prolia, Repatha |
| Astrazeneca Pharmaceuticals LP | $316.09 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $305.84 | 2019-2025 | |
| Novo Nordisk INC | $287.93 | 2019-2025 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $240.37 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $187.59 | 2019-2022 | |
| Glaxosmithkline, LLC. | $164.18 | 2019-2024 | Trelegy Ellipta, Shingrix, Bexsero |
| Medtronic, INC. | $96.19 | 2025 | Intellis Adaptivestim |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.17 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $86.42 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $60.98 | 2023-2024 | Gemtesa |
| Abbott Laboratories | $57.10 | 2023-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $56.21 | 2020-2022 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.